Genmab — Oktober 2017
-
Men kunne det være forklaring på at salget ROW næsten står stille. At Europa ser mere på cost/benefit?
-
Der er jo en grund til at NICE ikke har godkendt?
-
NICE har ikke godkendt, da de mener at 32% ORR ikke er tilstrækkeligt ifht omkostningen
-
Q&A er d. 9. november kl. 16.
-
Kan det være problemer med at producere nok?? og har det noget med EL notat 17:18
-
Der kan heller ikke være meget gang i combobehandlingerne endnu. Jeg ville have troet, at launchen ville forløbe hurtigere
-
European number, of course, great growth, $54 million in Q1, while the rest of world sales jumping to $87 million. So a really nice sort of 60% increase in Q2 versus Q1, which is great news. Majority of sales is still coming, and it's really driven by 2 countries, Germany and France. And those 2 combined are supplying slightly more than half of the rest of world sales at this point
-
Det giver mening,
Sukkeralf -
Man kan måske have en anelse om at der er gået noget cost/benefit i det. Måske på patienters bekostning..gud forbyde det!!
-
jep - det er den kategori, der hedder uden for pædagogisk rækkevidde
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind